ScholarLens Back to search
1993•Unpublished venueRequires access

Alprazolam vs imipramifie in treating depressive neurosis

Teng Pan, Hao Wei

Open publisher page 0 citations

Abstract

This paper reports a control trial of alprazolam (M 16, F 14, age 30.1 ±s1.9a, dose 2.4mg ± 1.2mg/d,6wk) vs imipramine (M 14, F 12, age 28.2 ± 1.7a, dose 175mg ± 25mg/d, 6wk)in treating patients with depressive neurosis. At the end of therapy, the total scores on HAMD and SDS of both groups decreased (F0. 01). The period from taking drugs to emergence of antidepressive effects and total response rates did not show significant differences between the 2 groups. TESS test showed that adverse reactions of alprazolam were less than those of imipramine.

About this research paper

What this paper is about

This paper reports a control trial of alprazolam (M 16, F 14, age 30.1 ±s1.9a, dose 2.4mg ± 1.2mg/d,6wk) vs imipramine (M 14, F 12, age 28.2 ± 1.7a, dose 175mg ± 25mg/d, 6wk)in treating patients with depressive neurosis. At the end of therapy, the total scores on HAMD and SDS of both groups decreased (F0. 01). The period from taking drugs to emergence of antidepressive effects and total response rates did not show significant differences between the 2 groups. TESS test showed that adverse reactions of alprazolam were less than those of imipramine.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This paper reports a control trial of alprazolam (M 16, F 14, age 30.1 ±s1.9a, dose 2.4mg ± 1.2mg/d,6wk) vs imipramine (M 14, F 12, age 28.2 ± 1.7a, dose 175mg ± 25mg/d, 6wk)in treating patients with depressive neurosis. At the end of therapy, the total scores on HAMD and SDS of both groups decreased (F0. 01). The period from taking drugs to emergence of antidepressive effects and total response rates did not show significant differences between the 2 groups. TESS test showed that adverse reactions of alprazolam were less than those of imipramine.

Key concepts: Alprazolam, Imipramine, Hamd, Neurosis, Medicine, Internal medicine, Psychiatry, Psychology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Alprazolam vs imipramifie in treating depressive neurosis — Research Paper | ScholarLens